Are activist shareholders poison for biotech?

Activist shareholder Carl Icahn has prompted fears that companies' ability to finance long-term research could be limited by the short-term investment horizons of shareholders like him, putting pressure on companies to boost their share prices quickly--sometimes at the expense of drug development. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.